Publications by authors named "Monica Montelongo"
Purpose: To evaluate patient-reported health-related quality-of-life (QoL) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced/metastatic breast cancer (ABC) treated with palbociclib in the longitudinal real-world study, POLARIS.
Methods: Data were prospectively collected from adult patients with HR+/HER2- ABC treated with palbociclib plus endocrine therapy (ET) in routine clinical practice. QoL was assessed with the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (EORTC QLQ-C30) and reported at baseline and months 6, 12, and 18.
Article Synopsis
- Strict eligibility criteria in RCTs limit data applicability to diverse real-world populations; thus, the POLARIS study focuses on hormone receptor-positive/HER2-negative advanced breast cancer patients receiving palbociclib and endocrine therapy.
- The study analyzed demographic and treatment data from 1,250 patients over a span of nearly three years, reporting response rates of 34.0% in first-line treatment and 21.8% in later lines, with median progression-free survival and overall survival varying by treatment line.
- Results indicate that outcomes in this diverse population align with previous clinical trial data, reinforcing the efficacy of palbociclib combined with endocrine therapy for patients with HR+/HER2- advanced breast cancer.
Article Synopsis
- The POLARIS study focuses on understanding the effects of palbociclib treatment on older patients with advanced breast cancer (ABC), particularly those aged 70 and over, who are often underrepresented in clinical trials.
- Researchers assessed geriatric impairments and daily living activities in these patients at baseline and after six months of treatment using specific evaluation tools (G8 and ADL).
- Results showed that among the oldest patients, there was stability in performance statuses, with a substantial proportion maintaining their functional abilities after six months of therapy, though no significant changes in mean scores were observed.
Article Synopsis
- * In the study, 15 male patients were observed, with a median age of 66. Most received palbociclib as a first-line treatment and reported manageable quality of life scores during the study, despite some experiencing adverse effects like neutropenia.
- * Results showed that 6.7% of patients achieved complete tumor response, while 53.3% had stable disease, and the median progression-free survival was about 19.
Background: Chronic venous leg ulcers (VLUs) are a common problem in clinical practice and available treatments are not satisfactory. The use of adjuvant therapies in combination with lower limb compression may lead to improved healing rates. Chronic wounds are candidates for new strategies in the emergent field of regenerative medicine.
View Article and Find Full Text PDF